Kornimate/medical-research-clean huggingface dataset:
microecology and host immunity in patients with severe covid-19 infection

Conditions: Microbiome,Immune Function, Critically Ill

Summary: the purpose of this study was to analyze the relationship between the microbial community, host immunity and the prognosis of patients with severe covid-19.

methods: bronchoalveolar lavage specimens of patients with severe covid-19 were collected and studied to analyze the relationship between the composition of patients' microecology and the occurrence and development of disease.

Eligibility criteria:
inclusion criteria: * 1) respiratory distress, respiratory rate ≥ 30 times/minute 2) at rest, oxygen saturation ≤ 93% 3）pao2/fio2 ≤300mmhg 4) shock 5) respiratory failure requires mechanical ventilation 6) complicated with other organ failure requires icu monitoring and treatment 7) or in case of any of the following conditions, even if none of the above conditions is found, it is also managed as a critical case: ① pulmonary imaging shows that the lesion has significantly progressed more than 50% within 24-48 hours; ② age\>60 years old; ③ complicated with serious chronic diseases (including diabetes, hypertension, coronary heart disease, malignant tumor, structural lung disease, pulmonary heart disease and immunosuppressed population) exclusion criteria: * 1) pregnant women 2) age\<18 3) mental disorders 4) patients with long-term mechanical ventilation for more than 60 days 5) disagreement group researcher
pt-cy with or without low-dose atg for lymphoid malignancies undergoing allo-hsct

Conditions: GVHD, Acute

Summary: all patients received flu-bu-vp16 as myeloablative conditioning followed by cyclophosphamide (d+3 and +4) and subsequent tacrolimus. for patients with unrelated or haplo-donor received low-dose atg at day +15.

for patients with high-risk lymphoid malignancies, patients will undergo allo-hsct from hla matched sibling, unrelated (9\~10/10) donor or hallo-identical donors. for all patients will receive myeloablative conditioning with 5-day fludarabine, 2-day vp-16 and 3-day busulifan. for prophylaxis graft versus host disease (gvhd), patients will receive cyclophosphamide 50mg/kg daily on d+3 and +4 with subsequent tacrolimus starting at d+5. for patients receiving hsct from unrelated or haplo-donor, low-dose atg 2.5mg/kg will be given on day +15.

Eligibility criteria:
inclusion criteria: * patients with lymphoid malignancies: cr1 or cr2 for acute lymphoblastic leukemia; t cell lymphoma (any cr/pr); b cell lymphoma (pr1 or cr2), hodgkin's disease (cr2 or beyond), sezary syndrome * patients with hla matched sibling, unrelated (hla 9\~10/10 matched) or haplo-identical donor exclusion criteria: * patients with active infection * patients with abnormal liver function damage: alt/ast above 2x normal range * patients with abnormal renal function damage scr\>160µmol/l; * patients with insufficient pulmonary function (fev1，fvc，dlco\<50%）and heart failure or with ef \<50%) * patients with mental instability * unwilling to give inform consent

Keywords: agvhd, cgvhd, pt-cy
immunological reset to allow access to hla compatible transplantation in highly sensitized kidney transplant candidates through non-myeloablative autologous stemm cell transplantation

Conditions: Kidney Disease; Kidney Transplant; Kidney Transplant Candidates

Summary: this is a study for hypersensitized patients who have been waiting for more than 3 years for an offer for a kidney transplant. the objective is to perform a transplant of autologous hematopoietic precursors with the aim of producing what we call an immunological reset to make the maximum number of anti-hla antibodies disappear and thus increase the chances of the patient receiving an offer for a kidney transplant.


Eligibility criteria:
inclusion criteria: 1. the patient must be able to understand and give written consent. 2. women and men between 18 and 65 years old. 3. patients with chronic kidney disease who are on renal therapy replacement with dialysis. 4. patient who is on the waiting list for kidney transplant from a death donor and who has not received an offer for a compatible transplant in the last 3 years within the national pathi prioritization program. 5. cpra calculated of more than 97% and having been in the program of prioritization for more than 3 years 6. positive igg serologies for cytomegalovirus and epstein barr. 7. women of childbearing potential must have a negative pregnancy test upon entry to the study and must agree to use safe contraceptive methods according to the guideline ctfg recommendations on contraception in clinical trials during duration of the study (condoms are considered safe methods male and female, oral contraceptives, etc.). 8. patients vaccinated against tetanus, influenza, pneumococcus and herpes zoster exclusion criteria: 1. current known infection, recurrent bacteria, virus, fungus or fungus bacteria, or other infections (such as hiv, hepatitis b, hepatitis c, or zoster). 2. concomitant serious uncontrolled major organ disease. 3. any infection that requires hospitalization and intravenous treatment with antibiotics during the 4 weeks prior to screening, or oral treatment with antibiotics the previous 2 weeks. 4. patients with primary or secondary immunodeficiencies. 5. patient with an active history of tuberculosis (even if treated) or patients with untreated latent tuberculosis. 6. malignancy during the 5 years prior to screening, except for carcinoma of the basal cell or squamous cell carcinoma properly removed. 7. known abuse of alcohol, drugs or chemicals within 1 year prior to screening. 8. patients with complicated peripheral venous access 9. neutropenia (anc \<1000/ul) or thrombocytopenia (platelet count \<100,000/ul) during the 4 weeks prior to screening. 10. severe allergic or anaphylactic reactions to human monoclonal antibodies, humanized or murine. 11. treatment with any investigational agent during the 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) prior to screening. 12. immunization with live vaccine during the 2 months prior to screening. 13. pregnant or breastfeeding women.

Keywords: hla tpha kidney transplant hypersensitized patient cpra immunosuppression dsa ahsct
mlc901 for moderate to severe traumatic brain injury (specified drug code)

Conditions: Traumatic Brain Injury

Summary: patients with a diagnosis of moderate to severe traumatic brain injury (tbi) will be enrolled. subjects will be randomly assigned to receive either mlc901 (specified drug code) or placebo capsules three times per day over 6 months. evaluation of patients will be carried out at baseline as well as at 3-month and 6-month follow-up visits. modified rankin scale (mrs) and glasgow outcome scale (gos) will be used to examine patients. efficacy will be evaluated by comparing these two scores between the 2 groups at follow-up visits.


Eligibility criteria:
inclusion criteria: * age between 15 and 65 * non-penetrating moderate (glasgow coma scale score \[gcs\] 9-12) or severe (gcs 3-8) traumatic brain * injury less than 24 hrs from traumatic injury * anticipated intensive care unit length of stay at least 48 hrs exclusion criteria: * gcs = 3 and fixed dilated pupils or penetrating injury * coexisting injury or medical conditions which could adversely affect our study outcome measures * dependence for everyday activities before the injury * pregnancy or breastfeeding * known allergy to any of mlc901 components
effect of acai berry consumption on blood glucose levels in healthy adults

Conditions: Post-prandial Glycaemia

Summary: type 2 diabetes mellitus is a chronic disease that results in hyperglycaemia. this study aimed to identify whether the anthocyanins contained in acai berries can mitigate postprandial glycaemia in healthy adults when consumed in conjunction with carbohydrate. study design was double blind randomised crossover with glycaemic levels assessed via capillary blood samples taken at baseline and over a 2 hour post-prandial period.

type 2 diabetes mellitus (t2dm) is a group of chronic metabolic disorders, characterised by insulin resistance and relative insulin deficiency, that results in hyperglycaemia. in the uk an estimated 4.3m people live with t2dm, and it is a major cause of kidney failure, heart attacks, stroke, blindness and lower limb amputation. the primary digestive enzymes that affect carbohydrate digestion and hence postprandial glycaemic levels have been identified as α-amylase and α-glucosidase. inhibition of these enzymes therefore reduces the rate of glucose absorption and is the principle behind t2dm medications such as acarbose, miglitol and voglibose. whilst acai berries have been found to be rich in α-amylase and α-glucosidase, no research has been conducted on healthy adults to ascertain whether the consumption of acai berries in conjunction with carbohydrate mitigates the rise in postprandial glycaemia. 10 participants were recruited for a double blind randomised crossover study where participants consumed smoothies containing either acai or placebo after 10 hours of fasting. capillary blood samples were taken at baseline then at 30 minutes intervals until 2 hours after consumption. the study included data for sex (female/male), age (years), weight (kg), height (cm), body mass index (kg/m2) and blood glucose (mmol/l). all data collection, smoothies preparation, smoothies consumption and blood sampling procedures were completed at st mary's university during the period november-december 2020. statistical analysis was conducted on the data for postprandial glycaemic response to ascertain whether the consumption of acai mitigated the glycaemic response relative to the placebo.

Eligibility criteria:
inclusion criteria: • bmi of 18.5 - 24.9 kg/m2. exclusion criteria: * known allergy to acai/berries or lactose. * pregnant or lactating. * alcohol/drug dependency. * smoking. * currently on an energy-restriction diet or have had a body weight change \>10% in last 2 months. * eating disorders. * diagnosed with diabetes or another chronic condition. * taking chronic medication. * allergy to any of materials used in, or an unsurmountable fear of, the finger-prick procedure.

Keywords: acai (euterpe oleracea), acute
specialized pro-resolving mediators (spm) as biomarkers of periodontal inflammation

Conditions: Inflammation; Periodontitis

Summary: periodontal diseases are a public health burden in all countries. hence, periodontitis is the sixth-most prevalent disease in the world, the most common bone diseases in human and the primary cause for tooth loss in adults leading to significant economic and medical consequences. all disease biomarkers could help to stratify the general population with those at high risk of periodontitis and to enroll them in a rigorous prevention program. advanced periodontitis has been shown to reduce the quality of life of patients and developing novel biological monitoring protocols will reduce the prevalence of advanced forms of the disease. there are alot of research explaining the different types of inflammatory mediators that could be found in periodontitis patients. but there are a few research have been talking about lipoxin a4 as an inflammatory biomarker that could detect the effect of non surgical periodontal therapy effect on the periodontal health. and the aim of the study is to assess the effect of this non surgical periodontal therapy on the periodontal health by assessing the concentration of this biomarker.


Eligibility criteria:
inclusion criteria: * control group : patients diagnosed as periodontally healthy * test group: * patients diagnosed with generalized periodontitis (stage 3/4, grade a,b or c). * having at least 15 remaining teeth. * mentally able to understand the communication and to express an informed consent exclusion criteria: * systemic diseases with known effect on periodontal health * antibiotics/anti-inflammatory drugs taken in the last month * women with suspected/known pregnancy, or taking any hormone-based treatment * patients suffering from xerostomia. * patients smoking more than 20 cig/day. * previous periodontal therapy in the last 3-6 months
preventative effect of combining dexamethasone with ondansetron on postoperative nausea, vomiting and shivering in children undergoing caudal anesthesia on hypospadias surgery

Conditions: Caudal Anesthesia

Summary: caudal epidural block is a technique used as an adjuvant to general anesthesia for postoperative analgesia in pediatric patients,especially those with infraumbilical, perineal and lower extremity surgery , because it reduces the need for perioperative and postoperative analgesia, reduces the need for general anesthesia, accelerates the awakening, suppresses the surgical neurohumoral stress response and can be performed easily the objective of the current study is to determine the efficacy and safety of prophylactic intravenous administration of combination of 0.1mg/kg of dexamethasone plus 4mg of ondansetron immediately before establishment of caudal block for prevention of nausea\&vomiting and shivering in pediatric patients undergoing infra umbilical surgeries

although it has some adverse effects: postoperative nausea and vomiting (ponv) are frequent and morbidity-related complication in children, ponv is still present in almost twice the frequency of adults, 33.2-82%. shivering is one of frequent, undesirable adverse effects, the incidence of shivering is up to 40-60% even in regional anaesthesia leads to o2 consumption and co2 production,so we target in this study two effective drugs with less side effects to reduse these adverse effects ondansetron is a highly potent selective 5 hydroxytryptamine receptor antagonist, which is widely used as an anti-emetic, its mechanism of action as anti-shivering is not clear and it is proposed to act centrally at the level of the pre-optic anterior hypothalamic region by inhibition of serotonin reuptake dexamethasone: is a potent class of steroid drugs ,it prevents thermoregulatory shivering via its central inhibitory effect on the thermoregulatory center and prevents non thermoregulatory shivering by its anti-inflammatory activity, i.e. antagonizing the activation of the inflammatory responses and release of cytokines during surgery the anti-emetic properties of dexamethasone are well established but the mechanisms underlying this anti-emetic effect remain largely unknown

Eligibility criteria:
inclusion criteria: - * age from 2 to 12 years old. * patients with stable vital signs. * patients with normal laboratory investigations. * patients undergoing caudal anaesthesia for infraumbilical surgeries exclusion criteria: - * patient's parental refusal. * age \ 12 years. * contraindications to caudal anaesthesia (coagulopathy, increased intracranial pressure, or local skin infection ,pilonidal cyst and congenital anomalies of lower spine because of unclear or impalpable anatomy * patients with cardiac morbidities. * failure of caudal block * diabetes mellitus * convulsions. * known allergy to any drugs used in this study.

Keywords: dexamethasone ondansetron
effect of dietary fiber on metabolism, inflammation and nutritional status in patients with chronic diseases

Conditions: Chronic Disease; Dietary Fiber

Summary: the prevalence of chronic disease is increasing rapidly in china. medical nutritional therapy (mnt) is essential for the prevention and control of chronic diseases. for example, dietary fiber plays an important role in chronic disease management. evidence suggests that increasing fiber intake can decrease the risk of chronic diseases, such as overweight/obesity, hyperlipidemia, hyperglycemia, gi diseases, etc. however, according to the nation-wide survey, the dietary fiber intake of chinese people shows a downward trend in recent years, and the relationship between dietary fiber and metabolism of chronic patients is still controversial. so, this study aims to explore the effects of dietary fiber on metabolism, inflammatory factors and nutritional status among patients with chronic diseases, so as to provide reference for proper nutrition intervention towards chronic disease.

investigators plan to recruit potential participants in hospital clinics using posters. an anticipated total of 120 patients with chronic diseases (including overweight, obesity, hyperlipemia, hyperglycemia, etc) will be randomized to receive oat beta-glucans (study group) or routine nutrition management (control group) respectively. the outcome parameters, including weight, blood glucose level, blood fat level, etc, will be measured and compared over a 12-week intervention period. intention-to-treat analysis (itt) and per-protocol analysis (pp) will be conducted in statistical analysis.

Eligibility criteria:
inclusion criteria: * age 18-70y * be diagnosed with obesity, hyperlipemia or hyperglycemia * fully understood and voluntarily signed the informed consent exclusion criteria: * secondary hyperlipidemia or hyperglycemia * multiple organ failure * allergic or intolerant to dietary fiber(dietary supplement) * have gastrointestinal diseases * have a history of abdominal diseases * experienced intra-abdominal surgery * pregnant and lactating women

Keywords: dietary fiber chronic disease metabolism inflammation nutritional status
effect of inspiratory muscle training on duration of mechanical ventilation support

Conditions: Respiratory Failure

Summary: a growing body of knowledge has documented that the diaphragm, the primary muscle of breathing, atrophies and weakens within days of instituting mechanical ventilation support. diaphragm weakness has been implicated as a major contributor to difficulty with weaning, or breathing without ventilator support. this study will test whether instituting a diaphragm strength training rehabilitation program will reduce the time patients require mechanical ventilation in a surgical intensive care setting.


Eligibility criteria:
inclusion criteria: 1. admission to general surgical intensive care unit with respiratory failure and expected to require mechanical ventilation support for more than 72 hours. exclusion criteria: 1. inability to follow simple, one step commands such as "inspire forcefully", 2. patients with prior arrangements to be transferred to other facilities when stabilized, 3. any contraindications to disconnecting pt from ventilator for sham or imst treatment, 4. unstable or difficult airway upon icu admission and predicted to last for more than 72 hours, 5. use of more than minimal vasopressor or vasodilatatory agents as a continuous infusion, 6. severe dysrhythmias, 7. acute coronary syndrome 8. pulmonary contraindications (pneumon/hemothorax, flail chest), 9. acute surgical problems arising in the immediate post operative period (serious postoperative bleeding, wound dehiscence, etc). when and if these problems resolve and the patient meets other entry criteria, they will be eligible to be recruited for participation. 10. active neuromuscular diseases that would prevent or interfere with responding to strength training (e.g., amyotrophic lateral sclerosis, multiple sclerosis, myasthenia gravis, polymyositis, muscular dystrophy or other dystrophies and myopathies) 11. spinal cord injuries.

Keywords: mechanical ventilation mechanical ventilation weaning inspiratory muscle strength training patients admitted to a surgical intensive care unit who are expected to receive mechanical ventilation for more than three days.
comparison of instillation and packing in mydriasis for premature infants

Conditions: Preterm Infants

Summary: the purpose of this study is to compare the mydriatic effect of 2.5% phenylephrine and 1% tropicamide by conventional instillation and lower conjunctival fornix packing in premature infants.

adequate pupil dilatation was needed for screening and treatment of retinopathy of prematurity (rop) in premature infants.in general clinical practice, mydriatic drugs were instilled many times until the pupil reached the maximum size. however, poor mydriasis were found in many eyes despite maximum instillation was used. from the clinical observation, we found the packing of mydriatic drugs in lower conjunctival fornix was much more effective to dilate the pupil than instillation in some patients. the purpose of this study was to compare the mydriatic effect of 2.5% phenylephrine and 1% tropicamide by conventional instillation and lower conjunctival fornix packing in premature infants.

Eligibility criteria:
inclusion criteria: * gestational age of less than 32 weeks and/or the birth weight of less than 1,500 grams * stable clinical course exclusion criteria: * history of intraocular surgery or laser treatment * previous eyedrop instillation that might affect the pupil size * severe underlying disease or unstable clinical course that mydriatic drugs or the examination could aggravate their conditions

Keywords: preterm infants mydriasis pupil dilation
the efficacy of asacol (mesalazine) suppository on the treatment of diarrhea-induced acute fissure

Conditions: Fissure in Ano; Diarrhea

Summary: anal fissure define as a superficial tearing in mucosa on the anoderm surface distal to dentate line . the most important factor is hard stool passing with trauma to anal mucosa. but, diarrhea diarrhea has been another important etiology that happen after some conditions like gastroenteritis, laxative over use, during chemotherapy, and ulcerative colitis exacerbation . in these conditions, it seems the change of stool ph maybe the main reason of inflammation and ulcer in acute phase. the treatment of acute is medical management with change in bowel habits and conservative therapy such as local lubricant, local vasodilator, and warm sitz bath to improve blood supply and wound healing. this research clinical trial is designed to show the effect of asacol suppository in the management of acute fissure due to diarrhea. the hypothesis of this research clinical trial has been referred to the cause of acute fissure ulcer because of diarrhea.

the cases with acute anal fissure after diarrhea will included in this research clinical trial. they will be divided in two groups as an interventional group and control by blind randomization allocation. the interventional group will have received asacol suppository 1 supp every night and diltiazem jelly (standard management) twice per day. the control group will have received diltiazem jelly and placebo suppository like interventional group. both group will have used warm sitz bath with enough hydration for 10 days. then the patients will have visited by another surgeon after 4 weeks to evaluate the healing of acute anal fissure. pain will have performed if the patients can tolerate.

Eligibility criteria:
inclusion criteria: for age between 18 and 65 years are the presence of acute anal fissure (with symptoms less than 6 weeks) following chronic diarrhea and subsequent fissure. exclusion criteria: * recurrent fissure with skin appendage. * long history of constipation. * use of immunosuppressive drugs or corticosteroids. * inflammatory bowel disease such as crohn's disease and ulcerative colitis. * pregnancy. * grade 3 and 4 hemorrhoids. * neurological disease. * obsessive-compulsive disorder. * previous history of anal surgery * skin diseases such as eczema and psoriasis. * sexually transmitted infections, tuberculosis. * mucosal prolapse. * anal fistula and pelvic radiotherapy.

Keywords: acute fissure diarrhea asacol